Materialise N.V.
MTLS scores 21.7 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -28.2 points significantly impact the ranking. Without these adjustments, MTLS would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| MTLS | 21.7 | 57.2 | 4.2% | 1.7% | $321M |
| MPWR | 85.1 | 91.7 | 21.2% | 81.0% | $56.6B |
| ZM | 84.5 | 18.0 | 3.1% | 21.7% | $22.4B |
| NVDA | 80.7 | 45.2 | 114.2% | 55.8% | $4.6T |
| CRUS | 80.3 | 19.1 | 6.0% | 17.5% | $7.3B |
| CSCO | 78.0 | 27.6 | 5.3% | 18.0% | $311.4B |
| ASML | 77.8 | 48.1 | 15.6% | 29.4% | $566.0B |
| RMBS | 77.7 | 48.3 | 20.7% | 32.3% | $11.0B |
| IDCC | 77.7 | 31.8 | -4.0% | 48.8% | $9.6B |
| ADI | 75.6 | 74.1 | 16.9% | 20.6% | $173.8B |
| FSLR | 75.3 | 17.3 | 26.7% | 30.7% | $22.3B |
| SIMO | 74.5 | 9.2 | 10.2% | 13.8% | $4.5B |
| AAPL | 74.4 | 33.1 | 6.4% | 27.0% | $4.0T |
| DBX | 74.0 | 13.9 | 1.9% | 17.7% | $6.7B |
| LRCX | 73.9 | 48.3 | 23.7% | 29.1% | $295.9B |
| TER | 73.7 | 90.9 | 5.4% | 19.2% | $53.1B |
| Sector Average | 48.1 | 49.8 | 14.8% | -110.0% | โ |
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
Stock is building a base after a decline. The 200-day moving average is flattening. Watch for a breakout above the 200-day SMA on increased volume.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $70M | $78M | $65M | $66M |
| Gross Profit | $40M | $44M | $38M | $37M |
| Operating Income | $2M | $3M | $3M | $574,000 |
| Net Income | $6M | $2M | $199,000 | $-533,000 |
| EPS (Diluted) | $0.09 | $0.04 | $0.00 | $-0.01 |
| Gross Margin | 58.1% | 56.8% | 58.3% | 55.3% |
| Operating Margin | 2.6% | 3.8% | 4.2% | 0.9% |
| Net Margin | 8.8% | 2.8% | 0.3% | -0.8% |
This stock has limited trading volume and/or float. Institutional investors may face difficulty entering or exiting positions without significant price impact. A post-hoc penalty has been applied to the composite score (this is not a backtested model factor โ it is a practical tradability overlay).
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $18.50 | $53.19 | 96.8% | Wide |
| 2022 | $8.36 | $24.84 | 99.3% | Wide |
| 2023 | $4.93 | $11.42 | 79.4% | Wide |
| 2024 | $4.70 | $8.50 | 57.6% | Wide |
| 2025 | $3.93 | $9.69 | 84.6% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.